{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T04:07:10Z","timestamp":1749096430090,"version":"3.41.0"},"reference-count":16,"publisher":"Gobierno de Navarra","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["An Sist Sanit Navar"],"published-print":{"date-parts":[[2021,8,20]]},"DOI":"10.23938\/assn.0948","type":"journal-article","created":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T17:40:36Z","timestamp":1623951636000},"page":"291-297","source":"Crossref","is-referenced-by-count":3,"title":["Pembrolizumab-associated autoimmune encephalitis in an elderly patient with advanced non-small cell lung cancer. A clinical case"],"prefix":"10.23938","volume":"44","member":"10024","reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. REDELMAN-SIDI G, MICHIELIN O, CERVERA C, RIBI C, AGUADO JM, FERN\u00c1NDEZ-RUIZ M et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors). Clin Microbiol Infect 2018; 24 (Suppl 2): S95-S107. https:\/\/doi.org\/10.1016\/j.cmi.2018.01.030","DOI":"10.1016\/j.cmi.2018.01.030"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. REYNOLDS KL, GUIDON AC. Diagnosis and management of immune checkpoint inhibitor-associated neurologic toxicity: illustrative case and review of the literature. Oncologist 2019; 24: 435-443. https:\/\/doi.org\/10.1634\/theoncologist.2018-0359","DOI":"10.1634\/theoncologist.2018-0359"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. MASUDA T, FUJITAKA K, ISHIKAWA N, NAKANO K, YAMASAKI M, KITAGUCHI S et al. Treatment rationale and design of the PROLONG study: Safety and efficacy of pembrolizumab as first-line therapy for elderly patients with non-small cell lung cancer. J Thorac Dis 2020; 12: 1079-1084. https:\/\/doi.org\/10.21037\/jtd.2019.12.46","DOI":"10.21037\/jtd.2019.12.46"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. TOPALIAN SL, HODI FS, BRAHMER JR, GETTINGER SN, SMITH DC, MCDERMOTT DF et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454. https:\/\/doi.org\/10.1056\/NEJMoa1200690","DOI":"10.1056\/NEJMoa1200690"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. MOLINA-GARRIDO MJ, SORIANO RODR\u00cdGUEZ MC, GUILL\u00c9N-PONCE C. \u00bfCu\u00e1l es el papel de la valoraci\u00f3n geri\u00e1trica integral en Oncogeriatr\u00eda? Rev Esp Geriatr Gerontol 2019; 54: 27-33. https:\/\/doi.org\/10.1016\/j.regg.2018.07.003","DOI":"10.1016\/j.regg.2018.07.003"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. BOSSART S. Case Report: Encephalitis, with brainstem involvement, following checkpoint inhibitor therapy in metastatic melanoma. Oncologist 2017; 22: 749-753. https:\/\/doi.org\/10.1634\/theoncologist.2016-0366","DOI":"10.1634\/theoncologist.2016-0366"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. BROWN MP, HISSARIA P, HSIEH AH, KNEEBONE C, VALLAT W. Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy. J Neuroinmunol 2017; 305: 16-18. https:\/\/doi.org\/10.1016\/j.jneuroim. 2016.12.016","DOI":"10.1016\/j.jneuroim.2016.12.016"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. NIKI M, NAKAYA A, KURATA T, NAKAHAMA K, YOSHIOKA H, KANEDA T et al. Pembrolizumab-induced autoimmune encephalitis in a patient with advanced non-small cell lung cancer: A case report. Mol Clin Oncol 2019; 10: 267-269. https:\/\/doi.org\/10.3892\/mco.2018.1777","DOI":"10.3892\/mco.2018.1777"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. YONEBU Y, ISHIJIMA M, TOYOOKA K, FUJIMURA H. [A case of meningoencephalitis associated with pembrolizumab treated for squamous cell lung cancer]. Clin Neurol 2019; 59: 105-108. https:\/\/doi.org\/10.5692\/clinicalneurol.cn-001218.","DOI":"10.5692\/clinicalneurol.cn-001218"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. SALAM S, LAVIN T, TURAN A. Limbic encephalitis following immunotherapy against metastatic malignant melanoma. BMJ Case Report 2016; 2016: bcr2016215012. https:\/\/doi.org\/10.1136\/bcr-2016-215012","DOI":"10.1136\/bcr-2016-215012"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. VOGRIG A, FOURET M, JOUBERT B, PICARD G, ROGEMOND V, PINTO AL et al. Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors. Neurol Neuroimmunol Neuroinflamm 2019; 6: E604. https:\/\/doi.org\/10.1212\/NXI.00000000000 00604","DOI":"10.1212\/NXI.0000000000000604"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. INOUYE SK, STUDENSKI S, TINETTI ME, KUCHEL GA. Geriatric syndromes: clinical, research, and policy implications of a core geriatric concept. J Am Geriatr Soc 2007; 55: 780-791. https:\/\/doi.org\/10.1111\/j.1532-5415.2007.01156.x","DOI":"10.1111\/j.1532-5415.2007.01156.x"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. KANAJI N, WATANABE N, KITA N, BANDOH S, TADOKORO A, ISHII T et al. Paraneoplastic syndromes associated with lung cancer. World J Clin Oncol 2014; 5: 197-223. https:\/\/doi.org\/10.5306\/wjco.v5.i3.197","DOI":"10.5306\/wjco.v5.i3.197"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. REMON J, LE RHUN E, BESSE B. Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era. Cancer Treat Rev 2017; 53: 128-137. https:\/\/doi.org\/10.1016\/j.ctrv.2016.12.006","DOI":"10.1016\/j.ctrv.2016.12.006"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. BENKE T, WAGNER M, PALLUA AK, MUIGG A, STOCKHAMMER G. Long-term cognitive and MRI findings in a patient with paraneoplastic limbic encephalitis. J Neurooncol 2004; 66: 217-224. https:\/\/doi.org\/10.1023\/b:neon.0000013488.52742.b4","DOI":"10.1023\/B:NEON.0000013488.52742.b4"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. DE OLIVERIA AM, PAULINO MV, VIERA APF, MCKINNEY AM, DA ROCHA AF, DOS SANTOS GT et al. imaging patterns of toxic and metabolic brain disorders. Radiographics 2019; 39: 1672-1695. https:\/\/doi.org\/10.1148\/rg.2019190016","DOI":"10.1148\/rg.2019190016"}],"container-title":["Anales del Sistema Sanitario de Navarra"],"original-title":[],"link":[{"URL":"https:\/\/recyt.fecyt.es\/index.php\/ASSN\/article\/view\/84284\/66219","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T06:28:04Z","timestamp":1749018484000},"score":1,"resource":{"primary":{"URL":"https:\/\/recyt.fecyt.es\/index.php\/ASSN\/article\/view\/84284\/66219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,20]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,8]]}},"URL":"https:\/\/doi.org\/10.23938\/assn.0948","relation":{},"ISSN":["1137-6627"],"issn-type":[{"type":"print","value":"1137-6627"}],"subject":[],"published":{"date-parts":[[2021,8,20]]}}}